- Home
- MIRM vs ESBA Comparison
MIRM vs ESBA Comparison
Compare MIRM & ESBA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIRM
- ESBA
- Stock Information
- Founded
- MIRM 2018
- ESBA N/A
- Country
- MIRM United States
- ESBA United States
- Employees
- MIRM N/A
- ESBA N/A
- Industry
- MIRM Biotechnology: Pharmaceutical Preparations
- ESBA
- Sector
- MIRM Health Care
- ESBA
- Exchange
- MIRM Nasdaq
- ESBA NYSE
- Market Cap
- MIRM 2.5B
- ESBA 2.6B
- IPO Year
- MIRM 2019
- ESBA 2013
- Fundamental
- Price
- MIRM $52.45
- ESBA $8.45
- Analyst Decision
- MIRM Strong Buy
- ESBA
- Analyst Count
- MIRM 11
- ESBA 0
- Target Price
- MIRM $57.00
- ESBA N/A
- AVG Volume (30 Days)
- MIRM 504.4K
- ESBA 4.5K
- Earning Date
- MIRM 02-26-2025
- ESBA 01-01-0001
- Dividend Yield
- MIRM N/A
- ESBA 1.60%
- EPS Growth
- MIRM N/A
- ESBA N/A
- EPS
- MIRM N/A
- ESBA 0.27
- Revenue
- MIRM $307,028,000.00
- ESBA $758,432,000.00
- Revenue This Year
- MIRM $83.04
- ESBA N/A
- Revenue Next Year
- MIRM $27.22
- ESBA N/A
- P/E Ratio
- MIRM N/A
- ESBA $32.38
- Revenue Growth
- MIRM 112.14
- ESBA 4.19
- 52 Week Low
- MIRM $23.14
- ESBA $7.85
- 52 Week High
- MIRM $54.23
- ESBA $11.50
- Technical
- Relative Strength Index (RSI)
- MIRM 64.07
- ESBA 23.51
- Support Level
- MIRM $51.02
- ESBA $8.70
- Resistance Level
- MIRM $53.76
- ESBA $9.53
- Average True Range (ATR)
- MIRM 2.04
- ESBA 0.12
- MACD
- MIRM 0.03
- ESBA -0.05
- Stochastic Oscillator
- MIRM 73.31
- ESBA 8.47
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter "IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.
About ESBA EMPIRE STATE REALTY OP LIM PARTNER
Empire State Realty OP LP is the operating partner of Empire State Realty Inc. The company along with its partner manages, operates, acquires and repositions properties in Manhattan and the greater New York metropolitan area. The firm operates in two segments, Real Estate and Observatory. Through the Real Estate segment, it offers services related to the ownership, management, operation, acquisition, repositioning and disposition of its real estate assets. Under the Observatory segment, it operates the two observatories of the Empire State Building. The company generates maximum revenue from the Real Estate segment.